Address
Email address
Phone number
Website
https://www.biopark.eeHome - BioParkTartu Biotechnology Park provides infrastructural, business development and consultancy services to companies and R&D institutions.
Name
aktsiaselts Biotehnoloogia Park Kinnisvara
Registry code
10834232
VAT number
EE100736533
Type
AS - Joint Stock Company
Status
Registered
Foundation date
07.01.2002 (23)
Financial year
01.01-31.12
Capital
148 248.00 €
Activity
68201 - Rental and operating of own or leased real estate
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Global HR Partner OÜ 11808343 | 50% - 74 124.00 EUR | - | - | Shareholder |
| OÜ KALTEC 10804159 | 50% - 74 124.00 EUR | - | - | FounderShareholder |
| Andrus Tasa
| - | Board member | - | |
| Jaanus Pikani
| - | - | - | Board member |
| Laila Tasa
| - | - | - | Board member |
| Olev Matt
| - | - | - | Board member |
| Icosagen AS 10565884 | - | - | - | Founder |
| OSAÜHING IMMUNOTRON 10697203 | - | - | - | Founder |
| aktsiaselts EGeen 10766766 | - | - | - | Founder |
| Sihtasutus Tartu Teaduspark 90001121 | - | - | - | Founder |
| Sihtasutus Geenikeskus 90001569 | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Celvia CC AS 11673707 | - | - | - | Founder |
| Sihtasutus Inicio 90011378 | - | - | - | Founder |
| osaühing TBD Pharmatech 11204964 | - | - | - | Founder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 100 040.6 € | 15 061.47 € | 1 321.92 € | 1 |
| 2024 Q3 | 92 968.86 € | 9 673.56 € | 1 321.92 € | 1 |
| 2024 Q2 | 96 200.21 € | 15 030 € | 1 321.92 € | 1 |
| 2024 Q1 | 116 898.3 € | 7 227.29 € | 1 321.92 € | 1 |
| 2023 Q4 | 96 623.19 € | 12 325.47 € | 1 321.92 € | 1 |
| 2023 Q3 | 84 417.08 € | 11 681.14 € | 1 321.92 € | 1 |
| 2023 Q2 | 96 744.22 € | 8 430.15 € | 1 321.92 € | 1 |
| 2023 Q1 | 129 223.74 € | 29 500.23 € | 660.96 € | 1 |
| 2022 Q4 | 119 005.06 € | 10 647.84 € | 660.96 € | 1 |
| 2022 Q3 | 108 590.76 € | 9 817.54 € | 660.96 € | 1 |
| 2022 Q2 | 117 508.06 € | 3 608.09 € | 660.96 € | 1 |
| 2022 Q1 | 138 759.66 € | 9 467.7 € | 660.96 € | 1 |
| 2021 Q4 | 118 421.11 € | 7 069.6 € | 660.96 € | 1 |
| 2021 Q3 | 85 283.66 € | 9 488.44 € | 660.96 € | 1 |
| 2021 Q2 | 79 985.15 € | 8 601.85 € | 660.96 € | 1 |
| 2021 Q1 | 89 624.08 € | 4 694.36 € | 660.96 € | 1 |
| 2020 Q4 | 85 511.02 € | 8 905.85 € | 660.96 € | 1 |
| 2020 Q3 | 84 471.23 € | 7 434.64 € | 660.96 € | 1 |
| 2020 Q2 | 88 540.47 € | 7 086.05 € | 1 514.21 € | 1 |
| 2020 Q1 | 91 856.12 € | 7 981.17 € | 1 484.61 € | 2 |
